Loading...
Loading...
- ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) announces preliminary preclinical data of TATX-03 PolyTope antibody cocktail program against SARS-CoV-2, the virus that causes COVID-19 disease.
- In the SARS-CoV-2 hamster model, treatment with TATX-03 resulted in complete clearance of detectable replication-competent virus from the lungs and throat of SARS-CoV-2 infected animals by day four post-infection.
- Furthermore, the study showed undetectable virus titer levels in the throat of 100% of the infected hamsters three days after virus infection.
- The results also demonstrated the TATX-03 antibody cocktail's potential to provide anti-viral effects against SARS-CoV-2 in both prophylactic (preventative) and treatment settings.
- The company said that 27 neutralizing lead candidate antibodies would be analyzed to generate full interaction profiles against seventeen different SARS-CoV-2 variants. Data is expected by early next month.
- IPA plans to start the final IND-enabling studies in late Q2 2021.
- Price Action: IPA increased 5.37% at $16.30 in market trading hours on last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in